For example, TLQP-21 modulates microglial function (76), TLQP-62 reduces Aβ plaque burden and disease-associated microglial activation (68), and other VGF peptides have been noted as decreasing in abundance in the brain, CSF, or blood plasma in AD or Parkinson's diseases (Table 2 in (78)). Here, VGF is linked to Alzheimer disease.